|Bid||0.00 x 2900|
|Ask||0.00 x 1000|
|Day's range||12.43 - 12.74|
|52-week range||8.63 - 14.27|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||4.05|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.83|
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
BOSTON, September 02, 2021--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: